ClinicalTrials.Veeva

Menu

Telehealth Approach to Enhancing Glycemic Control

W

White Plains Hospital

Status

Not yet enrolling

Conditions

Diabetes Mellitus

Treatments

Device: Continues glucose monitoring with remote glucose monitoring for 90 days

Study type

Interventional

Funder types

Other

Identifiers

NCT06830135
WPH IRB: 2025-16585

Details and patient eligibility

About

This study evaluates whether the use of a Continuous Glucose Monitoring (CGM) device combined with a Remote Patient Monitoring (RPM) program can improve blood sugar control and reduce hospital visits among patients with poorly controlled diabetes who have recently been discharged from the hospital.

The study, led by White Plains Hospital (WPH) Cares, will follow 208 patients for 90 days after their discharge. Half of the participants will receive standard care, while the other half will receive a Dexcom G7 CGM device along with support from trained nurses who will monitor their glucose readings daily. The goal is to determine whether this approach helps lower Hemoglobin A1c (HbA1c) levels, reduces hospital readmissions, and improves overall health outcomes.

Enrollment

208 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Discharged Home from the WPH Inpatient Setting A1c >= 8.0 within 90 days of discharge >= 18 Years of Age Lives within Westchester County

Exclusion criteria

  • <18 Years of Age Patient With Documented Cognitive Impairment or Decisional Incapacity Pregnant or Plans to Become Pregnant in 6 Months Discharge Disposition of Short-term or Long-term Care Facility, Assisted Living Facility, Group Home, Against Medical Advice/Eloped, or Home Hospice Patient or Caregiver Unable to Check Glucose at Home Using a Home Glucometer Lives Outside Westchester County

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

208 participants in 2 patient groups

Control Arm -standard of care
No Intervention group
Intervention Arm
Experimental group
Description:
Continuous glucose monitoring, remote patient monitoring for 90 days
Treatment:
Device: Continues glucose monitoring with remote glucose monitoring for 90 days

Trial contacts and locations

0

Loading...

Central trial contact

Katarzyna Zarychta, MS; Michelle Elsener, MBA, BSN, RN-BC, CPHQ

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems